Definitive Contract 75N93020C00040
Award Date 7/21/20
Potential Completion Date 12/31/26
Potential Value $26M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Baltimore, MD 21224, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $27,042,695.21 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Thomas Jefferson University for the advanced development of multivalent vaccine candidates for filovirus (e.g. Ebola) and Lassa fever. The contract does not have a set-aside designation. The contract involves the development, testing, and manufacturing of vaccine candidates, including Rabies Virus Based Platform Vaccines...
- This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Sanofi Pasteur Biologics, LLC, a foreign-owned for-profit organization. The contract is for the development and testing of a modified vaccinia Ankara (MVA) vaccine, with a ceiling value of $12,667,339.96. The contract is a definitive, cost-plus-fixed-fee contract type, with a final completion date of January 8, 2007. The...
- This is a $18,005,775.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization based in Australia. The contract is for the advanced development of the H7-Advax pandemic vaccine candidate through Phase 1 clinical trials, including the delivery of preliminary data regarding the adjuvant formulations and the manufactured product. The contract does not have a set-aside designation,...
- This is a $16,927,478.76 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Abvacc, Inc., a for-profit biotechnology company. The contract is to develop a potent therapeutic monoclonal antibody targeting the Marburg virus, a highly pathogenic filovirus. This award aligns with NIAID's efforts to advance medical countermeasures against biodefense and emerging infectious...
- This is a definitive, cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Public Health Vaccines LLC, a for-profit limited liability company. The purpose of this $101,433,355.76 contract modification is to exercise and fully fund Option 4/CLIN 0005 for the advanced research and development of an RVSV-MARV vaccine. The contract has an ultimate completion date of December 31, 2028 and was originally awarded on...
- This is a definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AlphaVax Human Vaccines Inc. for R&D in physical science and exploratory development. The contract has a ceiling value of $16,660,130.44 and an ultimate completion date of August 14, 2012. It was initially awarded on September 26, 2003 and does not have a set-aside designation. AlphaVax Human Vaccines Inc. is a for-profit organization that...
- This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...
- This is a $26,065,720.00 cost-plus-fixed-fee delivery order awarded to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The contract is for the manufacture of human flu challenge material, which supports IAVI's mission to develop safe and effective preventive vaccines for infectious diseases. The award is part of IAVI's existing indefinite...
- This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Sanofi Pasteur Biologics, LLC for the production and testing of a Modified Vaccinia Ankara (MVA) vaccine. The contract award has a ceiling value of $74,940,566.62 and an ultimate completion date of February 6, 2015. The contract is not designated as a set-aside. As a child company of the Sanofi group, Sanofi...